

(x) di - C<sub>1</sub>- C<sub>6</sub>- alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C<sub>1</sub>- C<sub>6</sub>- loweralkyl, hydroxy, C<sub>1</sub>- C<sub>6</sub>- alkoxy, benzyloxy, C<sub>1</sub>- C<sub>6</sub>- thioalkoxy and benzyl-S-, (xii) phenyl - C<sub>1</sub>- C<sub>6</sub>- alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di - C<sub>1</sub>- C<sub>6</sub>- alkylamino - C<sub>1</sub>- C<sub>6</sub>- alkyl, (xiv) C<sub>1</sub>- C<sub>6</sub>- alkoxy or benzyloxy and (xv) C<sub>1</sub>- C<sub>6</sub>- thioalkoxy or benzyl-S-;

E /  
Cont

n is 1, 2 or 3;

R<sub>2</sub> is hydrogen or C<sub>1</sub>- C<sub>6</sub>- loweralkyl;

R<sub>3</sub> is C<sub>1</sub>- C<sub>6</sub>- loweralkyl;

R<sub>4</sub> and R<sub>4a</sub> are independently selected from phenyl and substituted phenyl wherein the phenyl ring is substituted with a substituent selected from

(i) halo, (ii) C<sub>1</sub>- C<sub>6</sub>- loweralkyl, (iii) hydroxy, (iv) C<sub>1</sub>- C<sub>6</sub>- alkoxy or benzyloxy and (v) C<sub>1</sub>- C<sub>6</sub>- thioalkoxy or benzyl-S-;

R<sub>6</sub> is hydrogen or C<sub>1</sub>- C<sub>6</sub>- loweralkyl;

R<sub>7</sub> is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted or substituted with C<sub>1</sub>- C<sub>6</sub>- loweralkyl;

X is hydrogen and Y is -OH [ or X is -OH and Y is hydrogen, with the proviso that X is hydrogen and Y is -OH when Z is -N(R<sub>8</sub>)- and R<sub>7</sub> is unsubstituted and with the proviso that X is hydrogen and Y is -OH when R<sub>3</sub> is methyl and R<sub>7</sub> is unsubstituted ] ; and


Z is absent, -O-, -S-, -CH<sub>2</sub>- or -N(R<sub>8</sub>)- wherein R<sub>8</sub> is C<sub>1</sub>- C<sub>6</sub>- loweralkyl, C<sub>3</sub>- C<sub>7</sub>- cycloalkyl, -OH or -NHR<sub>8a</sub> wherein R<sub>8a</sub> is hydrogen, C<sub>1</sub>- C<sub>6</sub>- loweralkyl or an N-protecting group selected from the group consisting of formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl,  $\alpha$ -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, benzenesulfonyl, p-toluenesulfonyl, benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl,  $\alpha,\alpha$ -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl,

*E'*  
*Cont*

t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2.-trichloroethoxycarbonyl, phenoxy carbonyl, 4-nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantlyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl, benzyl, triphenylmethyl, benzyloxymethyl and trimethylsilyl;

or a pharmaceutically acceptable salt thereof.

2. (four times amended) A compound of the formula:



wherein R<sub>1</sub> is monosubstituted thiazolyl or monosubstituted oxazolyl wherein the substituent is selected from (i) C<sub>1</sub>-C<sub>6</sub>- loweralkyl, (ii) C<sub>2</sub>-C<sub>6</sub>- loweralkenyl, (iii) C<sub>3</sub>-C<sub>7</sub>- cycloalkyl, (iv) C<sub>3</sub>-C<sub>7</sub>- cycloalkyl - C<sub>1</sub>-C<sub>6</sub>- alkyl, (v) C<sub>5</sub>-C<sub>7</sub>- cycloalkenyl, (vi) C<sub>5</sub>-C<sub>7</sub>- cycloalkenyl - C<sub>1</sub>-C<sub>6</sub>- alkyl, (vii) C<sub>1</sub>-C<sub>6</sub>- alkoxy - C<sub>1</sub>-C<sub>6</sub>- alkyl or benzyloxy - C<sub>1</sub>-C<sub>6</sub>- alkyl, (viii) C<sub>1</sub>-C<sub>6</sub>- thioalkoxy - C<sub>1</sub>-C<sub>6</sub>- alkyl or benzyl-S - C<sub>1</sub>-C<sub>6</sub>- alkyl, (ix) C<sub>1</sub>-C<sub>6</sub>- alkylamino, (x) di - C<sub>1</sub>-C<sub>6</sub>- alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C<sub>1</sub>-C<sub>6</sub>- loweralkyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>- alkoxy, benzyloxy, C<sub>1</sub>-C<sub>6</sub>- thioalkoxy and benzyl-S-, (xii) phenyl - C<sub>1</sub>-C<sub>6</sub>- alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di - C<sub>1</sub>-C<sub>6</sub>- alkylamino - C<sub>1</sub>-C<sub>6</sub>- alkyl, (xiv) C<sub>1</sub>-C<sub>6</sub>- alkoxy or benzyloxy and (xv) C<sub>1</sub>-C<sub>6</sub>- thioalkoxy or benzyl-S-;

n is 1;

R<sub>2</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>- loweralkyl;

R<sub>3</sub> is C<sub>1</sub>-C<sub>6</sub>- loweralkyl;

R<sub>4</sub> is phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from (i) halo, (ii) C<sub>1</sub>-C<sub>6</sub>- loweralkyl, (iii) hydroxy, (iv) C<sub>1</sub>-C<sub>6</sub>- alkoxy or benzyloxy and (v) C<sub>1</sub>-C<sub>6</sub>- thioalkoxy or benzyl-S-;

R<sub>5</sub> is hydrogen, halo, C<sub>1</sub>-C<sub>6</sub>- loweralkyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>- alkoxy, benzyloxy, C<sub>1</sub>-C<sub>6</sub>- thioalkoxy or benzyl-S-;

R<sub>6</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>- loweralkyl;

R<sub>7</sub> is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted or substituted with C<sub>1</sub>-C<sub>6</sub>- loweralkyl;


E1  
Cont

X is hydrogen and Y is -OH ;

Z is absent, -O-, -S-, -CH<sub>2</sub>- or -N(R<sub>8</sub>)- wherein R<sub>8</sub> is C<sub>1</sub>-C<sub>6</sub>- loweralkyl, C<sub>3</sub>-C<sub>7</sub>- cycloalkyl, -OH or -NHR<sub>8a</sub> wherein R<sub>8a</sub> is hydrogen [ , ] or C<sub>1</sub>-C<sub>6</sub>- loweralkyl [ or an N-protecting group ] ; or a pharmaceutically acceptable salt thereof .

Please add the following new claims:

-- 33. A compound of the formula:



71960X  
wherein R<sub>1</sub> is monosubstituted thiazolyl or monosubstituted oxazolyl wherein the substituent is selected from (i) C<sub>1</sub>-C<sub>6</sub>- loweralkyl, (ii) C<sub>2</sub>-C<sub>6</sub>- loweralkenyl, (iii) C<sub>3</sub>-C<sub>7</sub>- cycloalkyl, (iv) C<sub>3</sub>-C<sub>7</sub>- cycloalkyl - C<sub>1</sub>-C<sub>6</sub>- alkyl, (v) C<sub>5</sub>-C<sub>7</sub>- cycloalkenyl, (vi) C<sub>5</sub>-C<sub>7</sub>- cycloalkenyl - C<sub>1</sub>-C<sub>6</sub>- alkyl, (vii) C<sub>1</sub>-C<sub>6</sub>- alkoxy - C<sub>1</sub>-C<sub>6</sub>- alkyl or benzyloxy - C<sub>1</sub>-C<sub>6</sub>- alkyl, (viii) C<sub>1</sub>-C<sub>6</sub>- thioalkoxy - C<sub>1</sub>-C<sub>6</sub>- alkyl or benzyl-S - C<sub>1</sub>-C<sub>6</sub>- alkyl, (ix) C<sub>1</sub>-C<sub>6</sub>- alkylamino, (x) di - C<sub>1</sub>-C<sub>6</sub>- alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C<sub>1</sub>-C<sub>6</sub>- loweralkyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>- alkoxy , benzyloxy, C<sub>1</sub>-C<sub>6</sub>- thioalkoxy and benzyl-S-, (xii) phenyl - C<sub>1</sub>-C<sub>6</sub>- alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di - C<sub>1</sub>-C<sub>6</sub>- alkylamino - C<sub>1</sub>-C<sub>6</sub>- alkyl, (xiv) C<sub>1</sub>-C<sub>6</sub>- alkoxy or benzyloxy and (xv) C<sub>1</sub>-C<sub>6</sub>- thioalkoxy or benzyl-S-;

n is 1, 2 or 3;

R<sub>2</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>- loweralkyl;

196

R<sub>4</sub> and R<sub>4a</sub> are independently selected from phenyl and substituted phenyl wherein the phenyl ring is substituted with a substituent selected from  
(i) halo, (ii) C<sub>1</sub>-C<sub>6</sub>- loweralkyl, (iii) hydroxy, (iv) C<sub>1</sub>-C<sub>6</sub>- alkoxy or benzyloxy and  
(v) C<sub>1</sub>-C<sub>6</sub>- thioalkoxy or benzyl-S-;

E2  
Cont

R<sub>6</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>- loweralkyl;

R<sub>7</sub> is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted and R<sub>3</sub> is C<sub>2</sub>-C<sub>6</sub>- loweralkyl and Z is absent, -O-, -S- or -CH<sub>2</sub>-;

or


R<sub>7</sub> is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is substituted with C<sub>1</sub>-C<sub>6</sub>- loweralkyl and R<sub>3</sub> is C<sub>1</sub>-C<sub>6</sub>- loweralkyl and Z is absent, -O-, -S-, -CH<sub>2</sub>- or -N(R<sub>8</sub>)- wherein R<sub>8</sub> is C<sub>1</sub>-C<sub>6</sub>- loweralkyl, C<sub>3</sub>-C<sub>7</sub>- cycloalkyl, -OH or -NHR<sub>8a</sub> wherein R<sub>8a</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>- loweralkyl or an N-protecting group selected from the group consisting of formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl,  $\alpha$ -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, benzenesulfonyl, p-toluenesulfonyl, benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl,  $\alpha,\alpha$ -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxy carbonyl, 4-nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantlyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl, benzyl, triphenylmethyl, benzyloxymethyl and trimethylsilyl ; and

X is -OH and Y is hydrogen;

or a pharmaceutically acceptable salt thereof .

34. A compound of the formula:

17



wherein R<sub>1</sub> is monosubstituted thiazolyl or monosubstituted oxazolyl wherein the substituent is selected from (i) C<sub>1</sub>-C<sub>6</sub>- loweralkyl, (ii) C<sub>2</sub>-C<sub>6</sub>- loweralkenyl, (iii) C<sub>3</sub>-C<sub>7</sub>- cycloalkyl, (iv) C<sub>3</sub>-C<sub>7</sub>- cycloalkyl - C<sub>1</sub>-C<sub>6</sub>- alkyl, (v) C<sub>5</sub>-C<sub>7</sub>- cycloalkenyl, (vi) C<sub>5</sub>-C<sub>7</sub>- cycloalkenyl - C<sub>1</sub>-C<sub>6</sub>- alkyl, (vii) C<sub>1</sub>-C<sub>6</sub>- alkoxy - C<sub>1</sub>-C<sub>6</sub>- alkyl or benzyloxy - C<sub>1</sub>-C<sub>6</sub>- alkyl, (viii) C<sub>1</sub>-C<sub>6</sub>- thioalkoxy - C<sub>1</sub>-C<sub>6</sub>- alkyl or benzyl-S- C<sub>1</sub>-C<sub>6</sub>- alkyl, (ix) C<sub>1</sub>-C<sub>6</sub>- alkylamino, (x) di - C<sub>1</sub>-C<sub>6</sub>- alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C<sub>1</sub>-C<sub>6</sub>- loweralkyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>- alkoxy, benzyloxy, C<sub>1</sub>-C<sub>6</sub>- thioalkoxy and benzyl-S-, (xii) phenyl - C<sub>1</sub>-C<sub>6</sub>- alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di - C<sub>1</sub>-C<sub>6</sub>- alkylamino - C<sub>1</sub>-C<sub>6</sub>- alkyl, (xiv) C<sub>1</sub>-C<sub>6</sub>- alkoxy or benzyloxy and (xv) C<sub>1</sub>-C<sub>6</sub>- thioalkoxy or benzyl-S-;

n is 1;

R<sub>2</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>- loweralkyl;

R<sub>4</sub> is phenyl or substituted phenyl wherein the phenyl ring is substituted with a substituent selected from (i) halo, (ii) C<sub>1</sub>-C<sub>6</sub>- loweralkyl, (iii) hydroxy, (iv) C<sub>1</sub>-C<sub>6</sub>- alkoxy or benzyloxy and (v) C<sub>1</sub>-C<sub>6</sub>- thioalkoxy or benzyl-S-;

R<sub>6</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>- loweralkyl;

R<sub>7</sub> is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted and R<sub>3</sub> is C<sub>2</sub>-C<sub>6</sub>- loweralkyl and Z is absent, -O-, -S-, or -CH<sub>2</sub>-;

or

R<sub>7</sub> is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is substituted with C<sub>1</sub>-C<sub>6</sub>- loweralkyl and R<sub>3</sub> is C<sub>1</sub>-C<sub>6</sub>- loweralkyl and Z is absent, -O-, -S-, -CH<sub>2</sub>- or -N(R<sub>8</sub>)- wherein R<sub>8</sub> is C<sub>1</sub>-C<sub>6</sub>- loweralkyl, C<sub>3</sub>-C<sub>7</sub>- cycloalkyl, -OH or -NHR<sub>8a</sub> wherein R<sub>8a</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>- loweralkyl; and

X is -OH and Y is hydrogen;

or a pharmaceutically acceptable salt thereof . . .